Data from a late-breaking abstract presented at the International Liver Congress 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' ...
Apr 12, 2014
0
0
Reducing chronic hepatitis B infections by screening at-risk adults, increasing hepatitis B vaccination rates, and linking infected persons to care is a public health priority, the American College of Physicians (ACP) and ...
Nov 20, 2017
0
0
(HealthDay)—A new test to help doctors identify the genotype of a person's hepatitis C infection has been approved by the U.S. Food and Drug Administration.
Jun 20, 2013
0
0
Like millions in Egypt, Ahmed Nada suffered silently from Hepatitis C. But the country is turning from the world's most afflicted by the disease to a global destination for those seeking a cure.
Sep 10, 2017
1
6
Among patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (development of excess fibrous connective tissue), sustained virological response (SVR) to interferon-based treatment was associated with ...
Dec 25, 2012
0
0
(HealthDay)—Of all the diseases people worry about getting, viral hepatitis is usually way down on the list. Most often it's thought of as a disease that affects only drug addicts or the sexually promiscuous. Though those ...
Dec 21, 2012
1
0
Helper cells traditionally thought to only assist killer white blood cells may be the frontline warriors when battling hepatitis A infection. These are the findings from a Nationwide Children's Hospital study appearing in ...
Jul 16, 2012
0
0
Prisoners are likely to be the primary risk group for HIV infections in Eastern Europe in the next 15 years, researchers from the University of Bristol have found.
Jul 27, 2016
0
3
Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis ...
Apr 25, 2015
0
11
Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with ...
Apr 25, 2015
0
5
